Research has also shown that PD-L2’s expression is not as restricted as initially thought and that, in pancreatic adenocarcinomas PD-L2 can be hyper-regulated in response to immunosuppressive cytokines released by a Th2-type response, contributing to the deactivation of the anti-tumor immune response [12, 18, 56]. The gene discussed is PDCD1LG2; the disease is pancreatic adenocarcinoma.